The FDA has approved lenalidomide (Revlimid®, Celgene Corporation) in combination with rituximab (R2) for adults previously treated for follicular lymphoma (FL) or marginal zone lymphoma (MZL). This is the first combination-treatment regimen for patients with these indolent forms of non-Hodgkin’s lymphoma (NHL) that does not involve chemotherapy.
Indolent lymphomas, which account for approximately 40% of all NHL cases, are slow-growing forms of the disease. Patients can often be asymptomatic or have fewer symptoms upon diagnosis.
Although chemotherapy is a standard of care for indolent forms of NHL, most patients either relapse or become refractory to their current treatment. Immune dysfunction is a defining aspect of FL and MZL; when it occurs, the immune system’s lymphocytes fail to detect or target cancerous cells.
The R2 approval is based largely on results from the randomized, double-blind, phase 3 AUGMENT study, which showed the combination significantly improved median progression-free survival (PFS) versus rituximab monotherapy. The median PFS was 39.4 months for patients treated with R2 and 14.1 months for patients treated with rituximab-placebo.
In participants with FL/MHL, adverse reactions included neutropenia, diarrhea, constipation, cough, fatigue, rash, pyrexia, leukopenia, pruritus, upper respiratory tract infections, abdominal pain, anemia, headache, and thrombocytopenia.
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweißen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.